medigraphic.com
Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado

2018, Number 1

<< Back Next >>

Rev Esp Med Quir 2018; 23 (1)

Recommendations from oncologists working at ISSSTE for the systemic management of advanced lung cancer

Aldaco-Sarvide F, Erazo Valle-Solís AA, Cárdenas E, Cruz-López JC, Enríquez-Aceves MI, González EF, Gómez-Rangel JD, Hernández-Flores O, Hernández-Luis G, López-Rodríguez L, Macedo-Pérez EO, Ramírez-Márquez M, Willars-Inman EL, Salamanca M, Mondragón P, Adame I

Language: Spanish
References: 133
Page: 26-40
PDF size: 219.19 Kb.


ABSTRACT

Background: Lung cancer is a health issue all over the world; its incidence and mortality increase uninterruptedly. In Mexico, it is one of the most frequent neoplasms. Material and methods: Specialists from ISSSTE conducted systematic bibliographic searches, which were distributed by subtopics in order to outline recommendations on pathology, molecular alterations of non-small cell lung cancer, molecular diagnosis, and imaging studies (positron emission tomography/computed tomography) which were assessed and accepted by consensus. Discussion: The therapeutic approach for advanced lung cancer not only requires an effective treatment but more accurate diagnostic tools which timely identified lesions in order to avoid cancer progression to more advanced stages. It is desirable that such methods be as comprehensive as possible and that they include imaging studies, immunohistochemistry panel, molecular and genetic analysis of the samples to determine the presence or absence of mutations, translocations, and amplifications to establish grade, treatment and prognosis. The ISSSTE experts’ treatment recommendations for advanced lung cancer are based on the GRADE system to unify criteria regarding diagnosis and treatment and include all the available drugs in our country. The access to these types of treatments should be carried out according to the codes and institutional and regulatory approvals; thus, the therapeutic options may vary or be different from these recommendations.


REFERENCES

  1. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3(4):524-48.

  2. Cancer Facts & Figures [Internet]. American Cancer Society; 2017 [Fecha consulta: julio de 2017]. Disponible en: https://www.cancer.org/research/ cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures- 2017.html

  3. Moctezuma VC, Patiño ZM. Cáncer de pulmón. Anales de Radiología México. 2009;1:33-45.

  4. Arrieta Rodríguez O, Guzmán de Alba E, Alba López LF, Acosta Espinoza A, Alatorre Alexander J, Alexander Meza JF, et al. Consenso nacional de diagnóstico y tratamiento del cáncer de pulmón de células no pequeñas. Rev Invest Clin. 2013;65(Suppl 1):S5-84.

  5. Kerr KM. Pulmonary adenocarcinomas: classification and reporting. Histopathology. 2009;54:12-27.

  6. Gellert A, Rudd RM, Sinha G, Geddes DM. Fibreoptic bronchoscopy: effect of multiple bronchial biopsies on diagnostic yield in bronchial carcinoma. Thorax. 1982;37(9):684-7.

  7. Sturgis CD, Nassar DL, D’Antonio JA, Raab SS. Cytologic features useful for distinguishing small cell from non-small cell carcinoma in bronchial brush and wash specimens. Am J Clin Pathol. 2000;114(2): 197-202.

  8. Cameron SEH, Andrade RS, Pambuccinan SE. Endobronchial ultrasound- guided transbronchial needle aspiration cytology: a state-of-theart review. Citopathology. 2010;21:6-26.

  9. Schreiber G, McCrory DC. Performance characteristics different modalities for diagnosis of suspected lung cancer. Chest. 2003;123(Suppl 1):115S-28S.

  10. Nicholson SA, Beasley MB, Brambilla E, Hasleton PS, Colby TV, Sheppard MN, et al. Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol. 2002;26(9):1184-97.

  11. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol. 2011;35:15-25.

  12. Terry J, Leung S, Laskin J, Leslie KO, Gown AM, Ionescu DN. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol. 2010;34(12):1805-11.

  13. Schwartz AM, Henson DE. Diagnostic surgical pathology in lung cancer: ACCP evidence-based clinical practice guidelines. Chest. 2007;132(Suppl 3):78S-93S.

  14. Saji H, Tsuboi M, Yoshida K, Kato Y, Nomura M, Matsubayashi J, et al. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer. J Thorac Oncol. 2011;6(11):1865-71.

  15. Travis WD, Muller-Hermelink HK. World Health Organization classification of tumors: pathology and genetics of tumors of the lung, pleura and heart. IARC Press, 2015.

  16. Naidoo J, Drilon A. Molecular diagnostic testing in non-small cell lung cancer [Internet]. Physicians’ Education Resource, LLC [Fecha consulta: julio de 2017]. Disponible en: http://www.gotoper.com/publications/ ajho/2014/2014sep/molecular-diagnostic-testing-in-non-small-cell- lung-cancer

  17. Goswami J. FDA’s Approval of First NGS-Based IVD for NSCLC Raises New Question: Where Does This Leave LDTs? [Internet]. Personalized Medicine Coalition [Fecha de consulta: julio de 2017]. Disponible en: https:// personalizedmedicine.blog/2017/07/11/fdas-approval-of-first-ngsbased- ivd-for-nsclc-raises-new-question-where-does-this-leave-ldts/

  18. Griffiths AJF, Miller JH, Suzuki DT, Lewontin RC, Gelbart WM. An Introduction to Genetic Analysis, 7th edition. New York: W. H. Freeman; 2000.

  19. Rivera P, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(Suppl 5):e142S-65S.

  20. Socinski MA. Incorporating immunotherapy into the treatment of non-small cell lung cancer: Practical guidance for the clinic. Semin Oncol. 2015;42(Suppl 2):S19-28.

  21. Ou SI, Schrock AB, Bocharov EV, Klempner SJ, Haddad CK, Steinecker G, et al. HER2 transmembrane domain (TMD) mutations (V659/G660) that stabilize homo- and heterodimerization are rare oncogenic drivers in lung adenocarcinoma that respond to afatinib. J Thorac Oncol. 2017;12(3):446-57.

  22. Shackelford RE, Vora M, Mayhall K, Cotelingam J. ALK-rearrangements and testing methods in non-small cell lung cancer: a review. Genes Cancer. 2014;5(1-2):1-14.

  23. von Schulthess GK, Steinert HC, Hany TF. Integrated PET/CT: Current applications and future directions. Radiology. 2006;238:405-22.

  24. Fischer B, Lassen U, Mortensen J, Larsen S, Loft A, Bertelsen A, et al. Preoperative staging of lung cancer with combined PET-CT. N Engl J Med. 2009;361:32-9.

  25. Socinski MA, Rivera MA, Halle JS, Detterberck FC, Falen S. Seeking a home for a PET, part 1: defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses. Chest. 2004;125(6):2294-9.

  26. Shreve PD, Anzai Y, Wahl R. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. RadioGraphics. 1999;19:61-77.

  27. Pinilla I, Gómez-León N. Utilidad de la PET/CT en el cáncer de pulmón. Radiología. 2009;51:248-60.

  28. Lung Cancer Screening CT Protocols Version 4.0 2/23/16.

  29. Evangelista L, Panunzio A, Polverosi R, Pomerri F, Rubello D. Indeterminate Lung Nodules in Cancer Patients: Pretest Probability of Malignancy and the Role of 18F-FDG PET/CT. NCCN. AJR Am J Roentgenol. 2014 Mar;202(3):507-14.

  30. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the Use of 18F-FDG PET in Oncology. J Nucl Med. 2008;49(3):480-508.

  31. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: Form and Function. Radiology. 2007;242:360-85.

  32. Sung YM, Lee KS, Kim BT, Kim S, Kwon OJ, Choi JY, et al. Nonpalpable supraclavicular lymph nodes in lung cancer patients: Preoperative characterization with F-FDG PET/CT. AJR. 2008;190:246-52.

  33. Yeh DW, Lee KS, Han J, Yi CA, Lee HY, Chung MJ, et al. Mediastinal nodes in patients with non–small cell lung cancer: MRI findings with PET/ CT and pathologic correlation. AJR. 2009;193:813-21.

  34. UyBico SJ, Wu CC, Suh RD, Le NH, Brown K, Krishnam MS. Lung cancer staging essentials: The new TNM staging system and potential imaging pitfalls. Radiographics. 2010;30:1163-81.

  35. Aquino SL, Kuester LB, Muse VV, Halpern EF, Fischman AJ. Accuracy of transmission CT and FDG-PET in the detection of small pulmonary nodules with integrated PET/CT. Eur J Nucl Med Mol Imaging. 2006;33(6):692-96.

  36. Gould MK, Kuschner WG, Rydzak CE, Maclean CC, Demas AN, Shigemitsu H, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 2003;139(11):879-92.

  37. Oriuchi N, Higuchi T, Ishikita T, Miyakubo M, Hanaoka H, Iida Y, et al. Present role and future prospects of positron emission tomography in clinical oncology. Cancer Sci. 2006;97:1291-7.

  38. Steinert HC, Kamel EH, de Juan R. PET and PET/CT of tumors of the chest. En: von Schulthess GK, editor. Clinical molecular anatomic imaging. Philadelphia: Lippincott Williams and Wilkins; 2003; pp. 291-305.

  39. de Leyn P, Strootbants S, de Weber W, Lerut T, Coosemans W, Decker G, et al. Prospective comparative study of integrated positron emission tomography-computed tomography scan compared with remediastinoscopy in the assessment of residual mediastinal lymph node disease after induction chemotherapy for mediastinoscopy-proven stage IIIA-N2 non-small-cell lung cancer: a Leuven Lung Cancer Group Study. J Clin Oncol. 2006;24:3333-9.

  40. Keidar Z, Haim N, Guralnik L, Wollner M, Bar-Shalom R, Ben-nun A, et al. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med. 2004;45:1640-6.

  41. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361:947-57.

  42. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30:1122-8.

  43. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol. 2013;24:54-9.

  44. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-8.

  45. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2010;11:521-9.

  46. Sequist LV, Yang JCH, Yamamoto N, O’Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327-34.

  47. Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, et al. Afatinib versus cisplatin plus gemcitabine for first- line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUXLung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213-22.

  48. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-46.

  49. Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, et al. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet. 2011;377(9780):1846-54.

  50. Langer CJ. The Lazarus response in treatment-naïve, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation. J Clin Oncol. 2009;27(9):1350-4.

  51. Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, et al. 135O_PR: plasma genotyping for predicting benefit from osimertinib in patients (pts) with advanced NSCLC. J Thorac Oncol. 2016;11(Suppl 4S):S154.

  52. Jänne PA, Yang JCH, Kim DW, Planchard D, Ohe Y, Ramalingam SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015;372:1689-99.

  53. Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, et al. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small- cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2016;17(12):1643-52.

  54. Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7:1807-14.

  55. Wu YL, Lee JS, Thongprasert S, Yu CJ, Zhang L, Ladrera G, et al. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial. Lancet Oncol. 2013;14(8):777-86.

  56. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12(11):1004-12.

  57. Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-94.

  58. Blackhall F, Kim DW, Besse B, Nokihara H, Han JY, Wilner KD, et al. Patient-reported outcomes and quality of life in PROFILE 1007: a randomized trial of crizotinib compared with chemotherapy in previously treated patients with ALK-positive advanced non-small-cell lung cancer. J Thorac Oncol. 2014;9(11):1625-33.

  59. Solomon BJ, Mok T, Kim DW, Wu YL, Nakagawa K, Mekhail T, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371(23):2167-77.

  60. Costa DB, Kobayashi S, Pandya SS, Yeo WL, Shen Z, Tan W, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29(15):e443-5.

  61. Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small- cell lung cancer (ASCEND-1): updated results from the multicenter, open-label, phase 1 trial. Lancet Oncol. 2016;17(4):452-63.

  62. Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T, et al. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: Results from the EUROS1 cohort. J Clin Oncol. 2015;33(9):992-9.

  63. Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014;371:1963-71.

  64. Lim SM, Kim HR, Lee JS, Lee KH, Lee YG, Min YJ, et al. Open label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol. 2017;35(23):2613-8.

  65. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small- cell lung cancer. N Engl J Med. 2016;375(19):1823-33.

  66. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26(28):4617-25.

  67. Gridelli C, Ardizzoni A, Le Chevalier T, Manegold C, Perrone F, Thatcher N, et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of a European Experts Panel. Ann Oncol. 2004;15(3):419-26.

  68. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced- stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543-51.

  69. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542-50.

  70. D’Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum- based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: A meta-analysis of the published literature. J Clin Oncol. 2005;23(13):2926-36.

  71. Liao B-C, Shao Y-Y, Chen H-M, Shau W-Y, Lin Z-Z, Kuo RN, et al. Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma. Clin Lung Cancer. 2015;16(2):137-43.

  72. Soon YY, Stockler MR, Askie LM, Boyer MJ. Duration of chemotherapy for advanced non-small-cell lung cancer: A systematic review and meta- analysis of randomized trials. J Clin Oncol. 2009;27(20):3277-83.

  73. Shepherd BFA, Dancey J, Ramlau R, Mattson K, Gralla R, Rourke MO, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum- based chemotherapy. Am Soc Clin Oncol. 2000;18(10):2095-103.

  74. Roszkowski K, Pluzanska A, Krzakowski M, Smith AP, Saigi E, Aasebo U, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer. 2000;27(3):145-57.

  75. Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, et al. Non-small cell lung cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(4):504-35.

  76. Reck M, Popat S, Reinmuth N, De Ruysscher D, Kerr KM, Peters S. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25 Suppl 3:iii27-39.

  77. Camps C, Felip E, García-Campelo R, Trigo JM, Garrido P. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2013. Clin Transl Oncol. 2013;15(12):977-84.

  78. Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S, Brahmer JR, et al. Systemic therapy for stage IV non-small-cell lung cancer: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 2015;33(30):3488-515.

  79. Wallace WAH. The challenge of classifying poorly in the lung. Histopathology. 2009;54:28-42.

  80. Travis WD. Reporting lung cancer pathology specimens. Impact of the anticipated 7th Edition TNM Classification based on recommendations of the IASLC Staging Committee. Histopathology. 2009;54:3-11.

  81. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-35.

  82. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540-50.

  83. Nivolumab [Opdivo®] [Internet]. National Comprehensive Cancer Network, JNCCN Non-Samll Cell Lung Cancer, JNCCN spotlights [Fecha publicación: Monday, March 20, 2017; fecha consulta: enero 2018]. Disponible en: http://jnccn360.org/nsclc/jnccn-spotlights/nivolumab/

  84. Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013;31(24):3004-11.

  85. Delbaldo C, Michiels S, Sys N, Soria JC, Le Chevalier T, Pignon JP. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA. 2004;292:470-84.

  86. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small- cell lung cancer. N Engl J Med. 2002;346:92-8.

  87. Fossella F, Periera JR, von Pawel J, Pluzanska A, Gorbounova V, Kaukel E, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21(16):3016-24.

  88. Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol. 1990;8(9):1556-62.

  89. Frasci G, Comella P, Panza N. Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia. Eur J Cancer. 1998;34:1710-4.

  90. Danson S, Middleton MR, O’Byrne KJ, Clemons M, Ranson M, Hassan J, et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced non- small cell lung carcinoma. Cancer. 2003;9(83):542-53.

  91. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007;18(2):317-23.

  92. Scagliotti GV, Kortsik C, Dark GG, Price A, Manegold C, Rosell R, et al. Pemetrexed combined with oxaliplatin or carboplatin as 1rst-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res. 2005;11(2 Pt 1):690-6.

  93. Cardenal F, López-Cabrerizo MP, Anton A, Alberola V, Massuti B, Carrato A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol. 1999;17(1):12-8.

  94. Pujol JL, Breton JL, Gervais R, Rebattu P, Depierre A, Morère JF, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol. 2005;16(4):602-10.

  95. Tan EH, Szczesna A, Krzakowski M, Macha HN, Gatzemeier U, Mattson K, et al. Randomized study of vinorelbine--gemcitabine versus vinorelbine-- carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer. 2005;49(2):233-40.

  96. Green M, Manikhas G, Orlov S, Afanasyev B, Makhson AM, Bhar P, et al. Abraxane®, a novel Cremophor® -free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006;17(8):1263-68.

  97. Rizvi NA, Riely GJ, Azzoli, CG, Miller VA, Ng KK, Fiore J, et al. Phase I/ II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage iv non-small-cell lung cancer. J Clin Oncol. 2008;26(4):639-43.

  98. Ardizzoni A, Boni L, Tiseo M, Fossella FV, Schiller JH, Paesmans M, et al. Cisplatin versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99(11):847-57.

  99. Zatloukal P, Kanitz E, Magyar P, Jassem J, Krzakowski M, Pawlicki M, et al Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. Lung Cancer. 1998;22(3):243-50.

  100. Hotta K, Matsuo K, Ueoka H, Kiura K, Tabata M, Tanimoto M. Meta- analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol. 2004;22(19):3852-9.

  101. Dancey J, Shepherd FA, Gralla RJ, Kim YS. Quality of live assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer. 2004;43(2):183-94.

  102. Di Maio M, Perrone F, Chiodini P, Galllo C, Camps C, Schuette W, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2007;25(11):1377-82.

  103. Corrales L, Nogueira A, Passiglia F, Listi A, Caglevic C, Giallombardo M, et al. Second-Line Treatment of Non-Small Cell Lung Cancer: Clinical, Pathological, and Molecular Aspects of Nintedanib. Front Med (Lausanne) 2017;4:13.

  104. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010 Jun;17(6):1471-4.

  105. Pignon JP, Arriagada R, Ihde DC, Johnson DH, Perry MC, Souhami RL, et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 1992;327(23):1618-24.

  106. Warde P, Payne D. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol. 1992;10(6):890-5.

  107. Marchioli CC, Graziano SL. Paraneoplastic syndromes associated with small cell lung cancer. Chest Surg Clin N Am. 1997;7(1):65-80.

  108. Titulaer MJ, Wirtz PW, Willems LN, van Kralingen KW, Smitt PA, Verschuuren JJ. Screening for small-cell lung cancer: a follow-up study of patients with Lambert-Eaton myasthenic syndrome. J Clin Oncol. 2008;26(26):4276-81.

  109. Stinchcombe TE, Gore EM. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist. 2010;15(2):187-95.

  110. Demedts IK, Vermaelen KY, van Meerbeeck JP. Treatment of extensive- stage small cell lung carcinoma: current status and future prospects. Eur Respir J. 2010;35(1):202-15.

  111. Postmus PE, Haaxma-Reiche H, Gregor A, Groen HJ, Lewinski T, Scolard T, et al. Brain-only metastases of small cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. Radiother Oncol. 1998;46(1):29-32.

  112. Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340(4):265-71.

  113. Saito H, Takada Y, Ichinose Y, Eguchi K, Kudoh S, Matsui K, et al. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol. 2006;24(33):5247-52.

  114. Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, et al. Randomized comparison of etoposide-cisplatin vs. etoposide- carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol. 1994;5(7):601-7.

  115. Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, et al. Phase II study of area under the plasma-concentration-versus-time curve- based carboplatin plus standard-dose intravenous etoposide in elderly patients with small-cell lung cancer. J Clin Oncol. 1999;17(11): 3540-5.

  116. Spigel DR, Bendell JC, McCleod M, Shipley DL, Arrowsmith E, Barnes EK, et al. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer. Clin Colorectal Cancer. 2012;11(1):45-52.

  117. Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, et al. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B trial 9732. J Clin Oncol. 2005;23(16):3752-9.

  118. Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 1985;3(11):1471-7.

  119. Schmittel A, Fischer von Weikersthal L, Sebastian M, Martus P, Schulze K, Hortig P, et al. A randomised phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer. Ann Oncol. 2016;17(4): 663-7.

  120. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346(2):85-91.

  121. Hanna N, Bunn PA, Langer C, Einhorn L, Guthrie T, Beck T, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/ cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24(13):2038-43.

  122. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, et al. CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992;10(8): 1225-9.

  123. Smit E, Fokkema E, Biesma B, Groen HJ, Snoek W, Postmus PE. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer. 1998;77(2):347-51.

  124. Yamamoto N, Tsurutani J, Yoshimura N, Asai G, Moriyama A, Nakagawa K, et al. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res. 2006;26(1B):777-81.

  125. Smyth JF, Smith IE, Sessa C, Schoffski P, Wanders J, Franklin H, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. Eur J Cancer. 1994;30A(8):1058-60.

  126. Pietanza MC, Kadota K, Huberman K, Sima CS, Fiore JJ, Sumner DK, et al. Phase II trial of temozolomide in patients with relapsed sensitive or refractory small cell lung cancer, with assessment of methylguanine- DNA methyltransferase as a potential biomarker. Clin Cancer Res. 2012;18(4):1138-45.

  127. Zauderer MG, Drilon A, Kadota K, Huberman K, Sima CS, Bergagnini I, et al. Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase. Lung Cancer. 2014;86(2):237-40.

  128. Jassem J, Karnicka-Młodkowska H, van Pottelsberghe C, van Glabbeke M, Noseda MA, Ardizzoni A, et al. Phase II study of vinorelbine (Navelbine) in previously treated small-cell lung cancer patients. EORTC Lung Cancer Cooperative Group. Eur J Cancer. 1993;29A(12):1720-2.

  129. Furuse K, Kuboa K, Kawahara M, Takada M, Kimura I, Fujii M, et al. Phase II study of vinorelbine in heavily previously treated small cell lung cancer. Oncology. 1996;53(2):169-72.

  130. van der Lee I, Smit EF, van Putten JW, Groen HJ, Schlösser NJ, Postmus PE, et al. Single-agent gemcitabine in patients with resistant small-cell lung cancer. Ann Oncol. 2001;12(4):557-61.

  131. Masters GA, Declerck L, Blake C, Sandler A, DeVore R, Miller K, et al. Phase II trial of Gemcitabine in patients with resistant small-cell lung cancer. J Clin Oncol. 2003;21(8):1550-5.

  132. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17(2):658-67.

  133. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small- cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016;17(7):883-95.




2020     |     www.medigraphic.com